Profession
D.C. aims to license pharma reps
NEWS IN BRIEF — Posted Jan. 7, 2008
The Washington, D.C., city council has taken the first step toward licensing pharmaceutical sales representatives. The bill, passed by the D.C. Council Health Committee on a 7-6 vote, also would bar the sale of physicians' prescribing information for data-mining by drugmakers unless a doctor allows the use under a so-called opt-in system.
Under the proposal, detailers would be required to sign an ethics code governing appropriate interactions with physicians, and would be regulated by a pharmacy board. The Pharmaceutical Research and Manufacturers of America opposes the bill.
AMA CEO Michael D. Maves, MD, MBA, wrote a letter to D.C. council members urging them to vote down the bill because of its potential adverse effect on research involving prescribing data.
"It is the AMA's position that an opt-in system would have substantially the same effect as an outright ban on the commercial use of these data, which would result in a major setback for the medical research community and the health outcomes that they are trying to improve," Dr. Maves wrote.
At press time, the bill was scheduled to see a vote in the full D.C. Council in early January.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2008/01/07/prbf0107.htm.












